Poseida Therapeutics, Inc. Sustainability Profile
Poseida Therapeutics, Inc., a pioneering biotechnology company headquartered in the United States, focuses on advancing cell and gene therapies. Founded in 2014, Poseida has made significant strides in the industry, particularly in the development of innovative therapies for cancer and genetic diseases. The company is renowned for its proprietary technologies, including its non-viral gene editing platform and its unique approach to cell therapy, which enhances the precision and efficacy of treatments. Poseida's commitment to harnessing the power of the immune system positions it as a leader in the rapidly evolving field of immunotherapy. With a robust pipeline of clinical candidates and strategic partnerships, Poseida Therapeutics continues to solidify its market position, aiming to transform the landscape of therapeutic options available to patients worldwide.
DitchCarbon Score
How does Poseida Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Poseida Therapeutics, Inc.'s score of 40 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Poseida Therapeutics, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Roche Holding AG, which may influence its climate commitments and strategies. While Poseida Therapeutics has not established its own reduction targets or climate pledges, it is important to note that it inherits sustainability initiatives from its parent company, Roche Holding AG. This includes potential targets set by Roche, which may align with industry standards for emissions reduction and climate action. As a part of the broader pharmaceutical industry, Poseida Therapeutics is expected to adhere to evolving climate commitments, particularly in light of increasing regulatory pressures and stakeholder expectations for transparency in carbon emissions and sustainability practices. However, specific details regarding their initiatives or targets remain unspecified at this time.
How Carbon Intensive is Poseida Therapeutics, Inc.'s Industry?
How Carbon Intensive is Poseida Therapeutics, Inc.'s Location?
Poseida Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Poseida Therapeutics, Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
